Uric Acid and Thiocyanate as Competing Substrates of Lactoperoxidase*

Received for publication, December 20, 2013, and in revised form, June 5, 2014. Published, JBC Papers in Press, June 13, 2014, DOI 10.1074/jbc.M113.544957

Antonia Seidel1‡1, Heather Parker‡, Rufus Turner§, Nina Dickerhof§, Irada S. Khalilova§, Sigurd M. Wilbanks§, Anthony J. Kettle§, and Guy N. L. Jameson‡2

From the 1Department of Chemistry, University of Otago, P. O. Box 56, Dunedin 9054, the 2Centre for Free Radical Research, Department of Pathology, University of Otago, Christchurch, Christchurch 8140, New Zealand, and the 3Department of Biochemistry, University of Otago, P. O. Box 56, Dunedin 9054, New Zealand

Background: Lactoperoxidase plays a key role in host defense by oxidizing thiocyanate to the bactericidal agent hypothiocyanite.

Results: Urate is a good substrate for lactoperoxidase and competes with thiocyanate for oxidation in vitro.

Conclusion: Urate is a likely physiological substrate for lactoperoxidase.

Significance: Urate may influence the bactericidal activity of lactoperoxidase.

The physiological function of urate is poorly understood. It may act as a danger signal, an antioxidant, or a substrate for heme peroxidases. Whether it reacts sufficiently rapidly with lactoperoxidase (LPO) to act as a physiological substrate remains unknown. LPO is a mammalian peroxidase that plays a key role in the innate immune defense by oxidizing thiocyanate to the bactericidal and fungicidal agent hypothiocyanate. We now demonstrate that urate is a good substrate for bovine LPO. Urate was oxidized by LPO to produce the electrophilic intermediates dehydrourate and 5-hydroxyisourate, which decayed to allantoin. In the presence of superoxide, high yields of hydroperoxides were formed by LPO and urate. Using stopped-flow spectroscopy, we determined rate constants for the reaction of urate with compound I (k1 = 1.1 × 107 M−1 s−1) and compound II (k2 = 8.5 × 103 M−1 s−1). During urate oxidation, LPO was diverted from its peroxidase cycle because hydrogen peroxide reacted with compound II to give compound III. At physiologically relevant concentrations, urate competed effectively with thiocyanate, the main substrate of LPO for oxidation, and inhibited production of hypothiocyanate. Similarly, hypothiocyanite-dependent killing of Pseudomonas aeruginosa was inhibited by urate. Allantoin was present in human saliva and associated with the concentration of LPO. When hydrogen peroxide was added to saliva, oxidation of urate was dependent on its concentration and peroxidase activity. Our findings establish urate as a likely physiological substrate for LPO that will influence host defense and give rise to reactive electrophilic metabolites.

Uric acid is an enigma in human metabolism. It accumulates in its mono-anionic form urate to produce high concentrations in cells and extracellular fluids such as lymphatic, interstitial, synovial, cerebrospinal, and respiratory tract lining fluids (1), but its precise physiological function remains unknown, although it is suggested to be an antioxidant (2–5) and a danger signal for inflammatory tissue damage (6). In contrast to other mammals, in humans urate is considered the end product of purine metabolism because the urate-catabolizing enzyme uricase has been lost during primate evolution (7, 8). High concentrations of plasma uric acid are associated with adverse outcomes in numerous inflammatory diseases (9–14), yet the mechanisms linking it to a particular pathology for the most part remain obscure. The major exception is activation of the NLRP3 inflammasome by uric acid crystals in gout (15–17).

Typical urate concentrations in human serum range from 50 to 900 μM (1). Concentrations of 200–300 μM are considered normal, whereas concentrations exceeding 420 μM are regarded hyperuricemic (18). Urate is also present in the airway lining fluids at substantial concentrations (40–370 μM) and is considered to be an abundant small-molecule antioxidant in the bronchoalveolar epithelial lining fluids (19). It can act as an antioxidant because its one-electron reduction potential ([E’] (urate/urate) = 0.56 V) is suitably poised for urate to intercept damaging radicals but not propagate chain reactions (20). This reduction potential also makes urate a likely substrate for heme peroxidases. Indeed, it was shown early that mammalian peroxidases oxidize urate to allantoin (21, 22). Recently, kinetic studies by us revealed urate to be a physiological substrate for the neutrophil enzyme myeloperoxidase (MPO)3 (23). It has also been suggested to be a substrate for the peroxidase cycle of prostaglandin synthase (24). Whether urate is an important physiological substrate for lactoperoxidase (LPO) is unknown.

LPO is a heme-containing mammalian enzyme found in exocrine secretion liquids, including saliva, tears, milk, and the lining fluids of the airway. Its main physiological function is the oxidation of thiocyanate (SCN−) to the bactericidal hypothiocyanate (−OCSN), which makes LPO an important part of the innate host defense (25–27). High concentrations of LPO are present in human airway secretions, suggesting a function of

* This work was supported by grants from the University of Otago and the Health Research Council of New Zealand.

1 Funded by a University of Otago International Doctoral Scholarship.

2 To whom correspondence should be addressed. Tel.: 64-3-479-8028; E-mail: gjameson@chemistry.otago.ac.nz.

3 The abbreviations used are: MPO, myeloperoxidase; LPO, lactoperoxidase; DTNB, 5,5′-dithiobis-2-nitrobenzoic acid; TMB, 3,3′,5,5′-tetramethylbenzidine; TNB, thio-2-nitrobenzoic acid; FOX, ferrous oxidation-xenylenol orange; ANOVA, analysis of variance.
Urate Oxidation by Lactoperoxidase

LPO in the airway host defense against respiratory diseases (28). Apart from its main substrate thiocyanate, LPO oxidizes a variety of organic substrates, such as serotonin, tyrosine, tryptophan, melatonin, tryptamine and N-acetylttryptamine (29), thioanisole (30), the antibiotic benzylpenicillin (31), and adrenaline (22). Given the promiscuity of LPO, we considered that it may also readily oxidize urate.

In this study, we raised the question as to whether urate is a likely physiological substrate for LPO and in what way this might affect the efficiency of the bactericidal activity of the enzyme. Our findings give new insights into human host defense in extracellular fluids and how they may be influenced by hyperuricemia.

EXPERIMENTAL PROCEDURES

Materials—Lactoperoxidase from bovine milk (purity index A$_{412}/A_{280}$ = 0.88 – 0.95) was purchased from Sigma (L8257) as lyophilized powder. Its concentration was determined using A$_{412}$ = 112,000 M$^{-1}$ cm$^{-1}$ (32). Initial experiments with human and bovine LPO showed near identical activity (33), and subsequent studies have used bovine LPO for kinetic studies. Myeloperoxidase was obtained from Planta (Vienna, Austria) and had a purity index of 0.82. Its concentration was determined using A$_{390}$ 89,000 M$^{-1}$ cm$^{-1}$ (34). Catalase (C3155), cytochrome c (C2506), 5,5-dithiobis-2-nitrobenzoic acid (DTNB, D8130), superoxide dismutase (S7571), uric acid (U2625), 3,3′,5,5′-tetramethylbenzidine (TMB, 860336), and xanthine oxidase (X1875) were also purchased from Sigma. To prevent artifactual oxidation of the substrate, 10 mM urate was dissolved in 40 mM sodium hydroxide containing 100 mM diethylenetriaminepentacetic acid and immediately diluted to the working concentration in 50 mM phosphate buffer, pH 7.4, or pH 7.0 for the kinetic studies, and stored in the dark. The concentrations of xanthine oxidase and cytochrome c were determined using A$_{450}$ = 70,000 M$^{-1}$ cm$^{-1}$ (35) and A$_{410}$ = 106,100 M$^{-1}$ cm$^{-1}$ (36), respectively. Hydrogen peroxide (30%) was purchased from BioLab, and the diluted solutions were prepared daily. The hydrogen peroxide concentration was determined by using A$_{240}$ = 43.6 M$^{-1}$ cm$^{-1}$ (37). Thio-2-nitrobenzoic acid (TNB) was prepared from 5,5-dithiobis-2-nitrobenzoic acid (DTNB, Ellman’s reagent) as described in Ref. 38.

Reaction of LPO with Urate and Identification of the Reaction Products by Mass Spectrometry—To identify the oxidation products, urate (400 mM) was oxidized by LPO (200 nM) and hydrogen peroxide (100 mM) in 50 mM phosphate buffer, pH 7.4, at 20 – 22 °C. Reactions were monitored after 10 min by the addition of 20 μg/ml catalase. The samples were suspended in 20% ammonium acetate buffer, pH 6.8, and 80% acetonitrile and centrifuged for 1 min at 16,000 × g. Urate, allantoin, and other intermediates were detected by liquid chromatography with mass spectrometry (LC/MS) as published previously (23). The urate oxidation products were monitored as described before but with the minor alteration of the chromatography by shortening the re-equilibration to 7 min and changing the source temperature of the mass spectrometer to 500 °C (23, 39). The [M-H]$^-$ ions that were monitored had m/z values of 167 (urate), 165 (dehydrourate), 183 (5-hydroxyisourate), and 157 (allantoin).

Urate Oxidation by LPO in the Presence of Superoxide—To investigate the formation of urate hydroperoxides by xanthine oxidase and LPO, organic hydroperoxides were detected using a ferrous oxidation-xylenol orange (FOX) assay as described previously (23, 37, 40 – 42). Reactions were started by adding acetaldehyde (3 mM) to LPO (150 nM) and urate (200 μM) in 50 mM phosphate buffer, pH 7.4.

Spectral Changes of LPO and Rate Constant for the Reaction of Compound I and II with Urate—The kinetic experiments were performed using equipment described previously (23) in 50 mM phosphate buffer, pH 7.0, at 25 °C. Urate photolysis (43) was minimized by using a filter with a cut-off at 320 nm. It was previously shown that equimolar concentrations of hydrogen peroxide were required to form the maximum amount of LPO compound I (29). This was confirmed by single mixing experiments, and the maximum amount of compound I and a minimal amount of compound II were present in the reaction mixture after 100 ms (data not shown). Consequently, a delay time of 100 ms was used for the double mixing experiments to study the reaction of compound I with urate. For the reaction of compound II with urate, either a delay time of 2 s was used so that the reaction mixture contained the maximum amount of compound II when the substrate was added, or compound II was produced by reaction with urate as described above.

The rate constants of the reactions of LPO compound I and II with urate were determined as described previously for urate oxidation by myeloperoxidase (23). Final concentrations were 1 μM ferric LPO, 1 μM hydrogen peroxide, and various concentrations of urate (0 – 25 μM). To monitor the reaction of LPO compound I with urate, spectral changes were followed between 1 ms and 1 s, and formation of compound II was monitored at 432 nm. To establish the rate constant of the reaction of LPO compound II with urate, spectral changes were monitored between 1 ms and 200 s, and the decay of compound II back to ferric LPO was observed at 432 nm. All data were fitted by single exponential functions to determine the pseudo-first-order rate constants k$_{obs}$, carried out at least in duplicate for each substrate concentration. Second-order rate constants were calculated from the slope of the linear fit when the mean values for k$_{obs}$ were plotted against substrate concentration.

Steady State Kinetics of the Reaction of LPO with Urate and with Thiocyanate—The steady state kinetics of urate oxidation by LPO were studied spectrophotometrically at room temperature in 50 mM phosphate buffer, pH 7.0. The reaction mixtures contained 500 nM LPO and 30 – 400 μM urate. Reactions were initiated by the addition of 100 μM hydrogen peroxide, and the velocity of urate turnover was measured at 291 nm (ε$_{291}$ = 12,300 M$^{-1}$ cm$^{-1}$) using an Agilent 8453 diode array spectrophotometer. Measurements were made every 20 s to avoid urate photolysis. Additionally, the steady state kinetics of the LPO/urate system were confirmed under the same reaction conditions at 25 °C by measuring the consumption of hydrogen peroxide using a hydrogen peroxide-sensitive electrode (ISO-HPO-2 hydrogen peroxide sensor, World Precision Instruments). To investigate whether LPO is inactivated by urate, activity assays using TMB were performed as described previously (44) before and 20 min after incubation of LPO (500 nM) with urate (100 μM) and hydrogen peroxide (100 μM).
For comparison with urate turnover, the steady state kinetics of thiocyanate oxidation by LPO were studied by measuring the consumption of hydrogen peroxide at 25 °C under the same buffer and pH conditions. In addition, the amount of hypothiocyanate formed was measured spectrophotometrically by assaying the oxidation of TNB ($e_{412} = 14,100 \text{ M}^{-1} \text{cm}^{-1}$) (38). The reaction mixtures contained 50 nM LPO, 100 μM hydrogen peroxide, 20–1000 μM potassium thiocyanate, and 100 μM TNB in 50 mM phosphate buffer, pH 7.0.

**Formation of Compound III during Steady State Oxidation of Urate**—To investigate the formation of LPO compound III during the steady state oxidation of urate, stopped-flow kinetic studies were performed in single mixing mode at 25 °C in 50 mM phosphate buffer, pH 7.0. After preincubation of LPO (2 μM final concentration) with urate (200 μM final concentration), the mixture was allowed to react with various concentrations of hydrogen peroxide (200–800 μM), and formation of compound III observed at 593 nm. The data were fitted with single exponential functions to determine the pseudo-first-order rate constant $k_{\text{obs}}$ which was repeated in triplicate for each hydrogen peroxide concentration. The slope of the mean values for $k_{\text{obs}}$ versus substrate concentration yielded the second-order rate constant for the reaction of compound II with hydrogen peroxide to form compound III.

**Competition of Urate and Thiocyanate for LPO**—To assess the competition between urate and thiocyanate for oxidation by LPO, the extent of urate oxidation was measured at a fixed concentration of urate and variable concentrations of thiocyanate. Allantoin was measured as a stable product of urate oxidation using liquid chromatography tandem mass spectrometry assay (LC/MS/MS) (39). Reactions were started by adding hydrogen peroxide (20 μM) to urate (400 μM) and LPO (50 nM) in 50 mM phosphate buffer, pH 7.4, in the presence of various concentrations of thiocyanate (0–200 μM) at 37 °C. After 30 min, reactions were stopped by the addition of 20 μg/ml catalase. The samples were suspended in 20% ammonium acetate buffer, pH 6.8, and 80% acetonitrile and centrifuged for 1 min at 16,000 × g, and the accumulated allantoin was quantified by LC/MS. The final concentrations of the product allantoin, which depend upon the relative rates of the respective reactions, were calculated for a range of thiocyanate concentrations, and the IC$_{50}$ was determined.

We also determined the competition between urate and thiocyanate by assaying the effect of urate on production of hypothiocyanite, which was quantified by measuring the conversion of GSH to GSSG. Reactions were started by adding 50 μM hydrogen peroxide to 200 μM GSH, 10 nM LPO, 100 μM thiocyanate, with or without the addition of 250 μM urate in 10 mM PBS (140 mM sodium chloride), pH 6.8. Reactions were stopped after 10 min by adding catalase (10 μg/ml). Conversion of GSH to GSSG was also measured after the addition of 2 μg/ml glucose oxidase to the above system to generate a continuous flux of hydrogen peroxide. In this case, reaction mixtures were incubated for 1 h at 37 °C. N-Ethylmaleimide (4 mM) was then added to alkylate unreacted GSH, and samples were incubated for 30 min in the dark and then stored at −20 °C until analyzed. Alkylated GSH and GSSG were analyzed by stable isotope dilution LC/MS/MS as described previously (45). Mass spectrometry analyses were performed using an Applied Biosystems 4000 QTRAP (Concord, Ontario, Canada) coupled to a Hypercarb column (150 × 2.1 mm, 3 μm, Thermo Scientific) operated at 60 °C.

**Bacterial Killing Assay**—We assessed the effect of urate on the bactericidal activity of LPO by measuring the hypothiocyanite-dependent killing of a clinical isolate of *Pseudomonas aeruginosa*. For viability assays, single colonies of *P. aeruginosa* were cultivated overnight in 3% tryptic soy broth (w/v; 37 °C; 200 rpm), harvested by centrifugation, washed, and suspended in Hanks’ balanced salt solution (10 mM PBS, pH 7.4, containing 500 μM MgCl$_2$, 1 mM CaCl$_2$, and 1 mg/ml glucose). Bacterial cell density was measured ($A_{550}$), and cell number was calculated from a standard curve based on colony counts. Hypothiocyanite was generated by adding 50 μM hydrogen peroxide to 10 nM LPO, 100 μM SCN, with or without 250 μM urate in PBS at pH 6.8. After 10 min at 20–22 °C, the remaining hydrogen peroxide was removed by the addition of 10 μg/ml catalase. *P. aeruginosa* were added to these solutions at a concentration of 1 × 10$^5$/ml and incubated for 2 h with constant rotation (37 °C, 6 rpm). Samples were then diluted in PBS, pH 6.8, and plated on blood agar, and colonies were counted after overnight incubation at 37 °C. *P. aeruginosa* were also exposed to a continuous flux of hypothiocyanite for 1 h with constant rotation (37 °C, 6 rpm) using glucose oxidase (2 μg/ml) and 10 nM LPO in the above buffer. This system generated 1.5 μM/min hydrogen peroxide. After the addition of catalase (10 μg/ml), samples were diluted in PBS, pH 6.8, plated on blood agar, and counted after overnight incubation at 37 °C.

**Analysis of Peroxidases and Urate Oxidation in Human Saliva**—Ethical consent was obtained to collect saliva from healthy subjects including an individual with MPO deficiency. The content of MPO protein in isolated neutrophils from the MPO-deficient individual was 3.5% of that from a healthy donor as assessed by an MPO ELISA assay (46). This value is similar to that previously reported for this individual (47). Saliva was collected at least 2 h after donors had eaten and immediately after they had rinsed their mouths with water. The saliva was centrifuged for 25 min at 25,000 × g, and the supernatant was analyzed for its content of peroxidase activity, urate, and allantoin. Peroxidase activity in saliva was measured by monitoring the oxidation of TNB ($e_{412} = 14,100 \text{ M}^{-1} \text{cm}^{-1}$) to DTNB in a 96-well plate (Falcon 353072) and a microplate spectrophotometer (SpectraMax 190, Molecular Devices) (38). Saliva was diluted ~10-fold into 50 mM phosphate buffer, pH 7.4, containing 100 mM thiocyanate and 100 μM TNB, and reactions were started by adding 50 μM hydrogen peroxide. The rate of production of hypothiocyanite was compared with standard curves obtained for bovine LPO and human MPO. Additionally, MPO concentrations in the saliva samples were measured using an activity ELISA as published previously (48). The concentration of LPO activity was then calculated by subtracting MPO activity from total peroxidase activity and expressed as bovine LPO equivalents. The concentrations of urate and allantoin in saliva supernatants were measured by mass spectrometry as described above. In a parallel experiment, hydrogen peroxide (50 μM) was added to the saliva samples and incubated for 30 min at 37 °C in the absence or presence of 1 mM sodium.
azide. Reactions were stopped by the addition of 10 μg/ml catalase, and the changes in allantoin concentrations were measured using liquid chromatography with mass spectrometry.

Statistical Analysis—Differences between treatment groups were determined using ANOVA followed by Holm–Šídák post hoc analysis. Differences from the control were considered significant when p < 0.05. Associations were analyzed using Pearson’s correlation coefficient and considered significant when p < 0.05.

RESULTS

Urate Oxidation by LPO and Hydrogen Peroxide was demonstrated by showing a decrease in absorbance at 290 nm and a corresponding increase at 315 nm due to formation of products as reported previously for MPO (23). Urate is known to readily photolyze (49), so precautions were made to minimize this by utilizing reduced light intensity. Under these conditions, in the absence of either LPO or hydrogen peroxide, no spectral changes were detected. The maximum initial rate of oxidation of urate by LPO occurred between pH 6 and 7, whereas an increase to pH 8 decreased the rate of urate oxidation (data not shown). LC/MS analysis of the reaction mixture revealed allantoin (m/z = 157) as the major stable reaction product, whereas dehydrourate (m/z = 165) and 5-hydroxyisourate (m/z = 183) were identified as reaction intermediates (data not shown). In the absence of either hydrogen peroxide or LPO, only minor quantities of the reaction products were detected, which correspond to a minimal amount of substrate degradation by UV light as well as auto-oxidation. These results confirm that urate is a substrate for LPO and is oxidized to electrophilic species that break down to allantoin (Fig. 1).

Urate Oxidation by LPO in the Presence of Superoxide—Previously, it was shown that when MPO oxidizes urate in the presence of superoxide, a hydroperoxide is formed by the addition of superoxide to the urate radical (23). To determine how effective LPO is at producing urate hydroperoxide, urate was oxidized by LPO in the presence of hydrogen peroxide and superoxide generated by xanthine oxidase and acetaldehyde. Hydroperoxides were quantified using the FOX assay, which is based on the oxidation of ferrous iron in the presence of xylenol orange (42). Considerable concentrations of hydroperoxides were formed by this system (Fig. 2), substantially more (~3-fold) than previously observed with MPO under similar conditions (23). When one of urate, LPO, xanthine oxidase, or acetaldehyde was omitted, hydroperoxide formation was prevented. The addition of catalase decreased hydroperoxide production to almost control levels, indicating a requirement for hydrogen peroxide. The addition of superoxide dismutase decreased hydroperoxide production to control levels, demonstrating that hydroperoxide formation was reliant on superoxide. Hence, LPO uses hydrogen peroxide and superoxide to oxidize urate to a hydroperoxide.

Spectral Changes of LPO and Rate Constant for the Reaction of Compound I and II with Urate—The rate constants for the reactions of urate with compound I and II were determined by stopped-flow kinetic studies. To determine the ideal delay times for the sequential mixing experiments, a single mixing experiment was performed where hydrogen peroxide was added to ferric LPO. Upon the addition of hydrogen peroxide to LPO, a decrease of absorbance was observed at 412 nm, which corresponds to the formation of compound I. The maximum concentration of compound I was found at 100 ms, which was therefore used as the delay time. After 100 ms, an absorbance shift from 412 nm to 432 nm was monitored and was completed in 2 s. These spectral changes indicate the conversion of compound I to II. In the absence of substrate, the absorbance of
compound II at 432 nm remained stable for 10 s and decayed very slowly afterward.

To determine the rate constant of the reaction of compound I with urate, ferric LPO was allowed to react with hydrogen peroxide for 100 ms followed by the addition of urate (0–25 \( \mu M \)) to reduce compound I. Spectral changes showed a rapid conversion of compound I (\( \lambda_{\text{max}} = 412 \) nm) to compound II (\( \lambda_{\text{max}} = 432 \) nm) over 50 ms (Fig. 3A). Kinetic traces were monitored at 432 nm to follow compound II formation and fitted with single exponential functions (Fig. 3B). The observed pseudo-first-order rate constants \( k_{\text{obs}} \) were plotted against the concentration of urate (black dots). Data are means and ranges of at least duplicate measurements. The slope of the linear fit corresponds to the second-order rate constant of the reaction of LPO compound I with urate.

Previously, it was suggested that compound I of LPO can isomerize so that the porphyrin radical is transferred to an amino acid residue and that this species is spectrally identical to compound II (50). Therefore, a species with spectral characteristics of compound II was formed either through decay of compound I by increasing the delay time to 2 s or by reduction of compound I by urate as described above. The former method could give isomerized compound I or authentic compound II, whereas the second method would give authentic compound II only. In both cases, upon the addition of urate (0–200 \( \mu M \)) to compound II, spectral changes revealed its conversion (\( \lambda_{\text{max}} = 432 \) nm) back to the ferric enzyme (\( \lambda_{\text{max}} = 412 \) nm) over 60 s, as well as an isosbestic point at 423 nm (Fig. 4A). Kinetic traces were monitored at 432 nm to follow the reduction of compound II and were fitted with single exponential functions (Fig. 4B).
**Urate Oxidation by Lactoperoxidase**

The observed pseudo-first-order rate constants $k_{\text{obs}}$ were independent of the method in which compound II was formed and revealed a linear dependence on substrate concentration for up to 30 $\mu$M urate (Fig. 4C). The line of best fit had a slope of $(8.5 \pm 0.4) \times 10^3$ M$^{-1}$ s$^{-1}$, which represents the second-order rate constant of the reaction of LPO compound II with urate. The intercept of the fitted line with the y constant of the reaction of LPO compound II with urate. The $k_{\text{obs}}$ versus urate concentration for the reaction of compound II with urate plateaus (Fig. 4D), indicating a binding interaction between compound II and urate, which can be described as follows (52–54).

\[
\text{CmpdII + Urate} \rightarrow \text{CmpdII:Urate} \rightarrow \text{Ferric + Urate Radical}
\]

**REACTION 1**

As a result, $k_{\text{obs}}$ versus urate concentration can be fitted to a rectangular hyperbola, according to the following equation.

\[
k_{\text{obs}} = \frac{k_{\text{rin}}}{k_{\text{app}}} \frac{[\text{Urato}]+1}{k_{\text{rin}}}
\]

(Eq. 1)

where

\[
k_{\text{app}} = \frac{k_{\text{rin}}}{k_{\text{rin}} + k_{\text{rxn}}}
\]

(Eq. 2)

The value for the apparent dissociation constant $K_{\text{app}} = (200 \pm 30)$ $\mu$M was directly derived from the nonlinear fit shown in Fig. 4D. We would expect a similar plot of $k_{\text{obs}}$ versus urate concentration to level off at high urate concentrations for the reaction of compound I with urate. Unfortunately, we were not able to measure these rate constants because of the high reactivity of urate toward urate, leading to rates that are beyond the detection limit of the instrument at high urate concentrations.

**Steady State Kinetics of the Reaction of LPO with Urate and with Thiocyanate**—To understand how urate and thiocyanate may compete as substrates for LPO, the steady state kinetics of their oxidation by the enzyme were studied and compared. Hydrogen peroxide consumption was measured for both substrates using a hydrogen peroxide-sensitive electrode (Fig. 5A). Additionally, urate oxidation was followed directly at 291 nm, and the formation of hypothiocyanite was monitored by recording its oxidation of TNB. The Michaelis-Menten curves are shown in Fig. 5, B and C, and the kinetic parameters, which were independent of the methods used to measure them, are listed in Table 1. These parameters reveal that thiocyanate is preferred to urate as a substrate for LPO but suggest that, depending on relative concentrations, the two substrates should compete for oxidation by the enzyme. The kinetic traces of urate oxidation were characterized by an initial phase of fast urate depletion followed by a slower second phase. To investigate whether the slow phase was due to irreversible enzyme deactivation whether the slow phase was due to irreversible enzyme deactivation...
TABLE 1
Steady state kinetic parameters for the oxidation of urate and thiocyanate by LPO

|                      | LPO + urate (initial phase) | LPO + urate (secondary phase) | LPO + SCN⁻ |
|----------------------|-----------------------------|-------------------------------|------------|
| $K_m$ (µM)           | 100 ± 20                    | 220 ± 30                      | 340 ± 60   |
| $V_{max}$ (s⁻¹)      | 0.56 ± 0.06                 | 0.13 ± 0.01                   | 180 ± 20   |
| $k_{cat}$ (M⁻¹ s⁻¹)  | 5.6 × 10³                   | 580                           | 5.5 × 10⁵  |

Inhibition, activity assays using TMB were performed before and after reaction of LPO with urate. No change in peroxidase activity occurred after reaction with hydrogen peroxide and urate (data not shown).

Formation of Compound III during Steady State Oxidation of Urate—To understand why urate oxidation by LPO was characterized by an initial fast phase, we monitored the enzyme spectrally and observed that it was present as compound III during the steady state of urate turnover by LPO (Fig. 6A). When LPO and urate were allowed to react with various concentrations of hydrogen peroxide, spectral changes revealed a conversion of compound II ($\lambda_{Soret} = 432$ nm, $\lambda_{B} = 542$ nm, $\lambda_{G} = 574$ nm) to compound III ($\lambda_{Soret} = 428$ nm, $\lambda_{B} = 555$ nm, $\lambda_{G} = 593$ nm) over 60 s, as well as an isosbestic point at 431 nm (Fig. 6A). Kinetic traces were monitored at 593 nm and fitted with single exponential functions for each hydrogen peroxide concentration (Fig. 6B). The observed pseudo-first-order rate constants $k_{obs}$ of compound III formation were linearly dependent on the concentration of hydrogen peroxide (Fig. 6C), and the linear fit had a slope of $(220 ± 15)$ M⁻¹ s⁻¹. This value corresponds to the second-order rate constant of the reaction of LPO compound II with hydrogen peroxide to form compound III (55). The intercept of the fitted line with the y axis was $-0.007 ± 0.008$ s⁻¹. The fact that the fitted line intercepts the origin strongly suggests that compound III is formed only by the reaction of compound II with hydrogen peroxide.

Urate and Thiocyanate as Competing Substrates for LPO—Next we investigated the direct competition between urate and thiocyanate for oxidation by LPO. First, we determined the effect of thiocyanate on urate oxidation by measuring its ability to inhibit the accumulation of allantoin. Reactions were allowed to proceed long enough so that all the hydrogen peroxide was used by LPO. In the absence of thiocyanate, about half the hydrogen peroxide was accounted for by the accumulation of allantoin. Thiocyanate inhibited the extent of allantoin formation in a concentration-dependent manner. It inhibited by 50% at a concentration of 36 µM (IC₅₀) when 400 µM urate and 20 µM hydrogen peroxide were present in the reaction mixture (Fig. 7). The obtained IC₅₀ was confirmed assuming only direct competition between thiocyanate and urate with compound I and using the respective rate constants ($k_{SCN} = 2.0 × 10³$ M⁻¹ s⁻¹; $k_{urate} = 1.1 × 10⁸$ M⁻¹ s⁻¹). These values yield a calculated IC₅₀ of 24 µM.

To confirm the influence of urate on the capability of LPO to oxidize thiocyanate, the production of hypothiocyanite by LPO was measured by detecting the oxidation of GSH to GSSG in the absence and presence of urate. Reactions were run for sufficient time so that the LPO/thiocyanate system could just consume all added hydrogen peroxide. In the absence of urate, LPO used hydrogen peroxide and thiocyanate to produce super-stoichiometric concentrations of GSSG (Fig. 8A). This result is in accord with the formation of a radical intermediate of thiocya-
Urate Oxidation by Lactoperoxidase

In the presence of urate, hypothiocyanite production was substantially decreased when a bolus of hydrogen peroxide was added (Fig. 8A), confirming that urate is capable of competing with thiocyanate for oxidation. When glucose oxidase was used to generate a flux of hydrogen peroxide and ensure a low steady state concentration of this substrate, urate also inhibited the production of hypothiocyanite (Fig. 8B). In both cases, urate inhibited considerably more than the 10% that would be expected if it was acting only by competing with thiocyanate for oxidation by compound I. Thus, urate inhibits production of hypothiocyanite via a pathway in addition to its reaction with compound I.

Inhibition of LPO-dependent Bacterial Killing by Urate—To investigate whether urate affects the ability of LPO to kill pathogenic bacteria, we determined the extent to which it prevented killing of P. aeruginosa by LPO, thiocyanate, and hydrogen peroxide. Under the conditions of our assay, LPO promoted substantial killing of P. aeruginosa in the presence of thiocyanate and hydrogen peroxide (Fig. 9A). A similar degree of killing was observed when hydrogen peroxide was supplied slowly by glucose oxidase (Fig. 9B). In both cases, killing was reliant on the presence of LPO, thiocyanate, and hydrogen peroxide. Urate, at normal physiological concentrations (1, 19), inhibited killing either in the presence of a bolus of hydrogen peroxide or when it was generated as a slow flux. These results suggest that at physiologically likely concentrations of both urate and thiocyanate, urate will interfere with the hypothiocyanite-dependent killing of bacteria by LPO.

Peroxidase Levels and Urate Oxidation in Human Saliva—To establish the physiological importance of urate oxidation by LPO, we measured urate oxidation in human saliva. Previously, it was demonstrated that saliva supernatants contain predominantly LPO with variable concentrations of MPO. No other proteins with peroxidase activity were detected, including eosinophil peroxidase (58). All our subjects had detectable concentrations of LPO activity in saliva supernatants in agreement with previous studies (Fig. 10A) (58, 59). Four subjects, including one with MPO deficiency, had very low levels of detectable MPO activity. Allantoin was present in saliva supernatants and was associated with the activity of LPO (r = 0.77; p = 0.001) (Fig. 10B) but not MPO (not shown). When hydrogen peroxide was added to saliva supernatants, there was a significant increase in allantoin that did not occur in the presence of azide, a peroxidase poison (Fig. 10C). The concentration of allantoin increased in all samples, including those from individuals with low MPO and that from a person with MPO deficiency. The increase in allantoin concentration upon the addition of hydrogen peroxide to the saliva was dependent on its concentration of urate (r = 0.73; p = 0.003) (Fig. 10D) but not the concentrations of peroxidases (not shown). Collectively, these results suggest that the LPO present in saliva promotes the oxidation of urate.

DISCUSSION
In this investigation, we have shown that urate is an excellent substrate for compound I of LPO as part of the classical perox-
Urate Oxidation by Lactoperoxidase

idase cycle and can therefore be expected to be a physiological substrate for the enzyme. Urate also reacts well with compound II, but this reaction is in competition with the conversion of compound II to compound III by hydrogen peroxide (Fig. 11). Based on our current findings and the demonstration that urate is a substrate for MPO, urate should now be recognized as a peroxidase substrate that will influence the activity of these enzymes and give rise to potentially toxic electrophiles. Urate also reacts well with compound III to form the reactive urate radical (20). This compound is shown to be toxic in several assays (20). However, in a physiological environment, antioxidants such as ascorbate may interfere by reducing urate radicals and limiting the formation of the electrophilic species of urate. The effects of ascorbate on the LPO/urate system will be the subject of future studies.

As described previously for other peroxidases, the urate radicals produced by LPO will give rise to dehydrourate, 5-hydroxyisourate, and allantoin as outlined in Fig. 1 (23, 60). Dehydrourate and 5-hydroxyisourate are electrophilic species that are potentially toxic and are likely to affect host defense as well as the inflammatory response to bacteria. The absence of 5-hydroxyisourate hydrolyase in knock-out mice predisposes them to liver cancer (61), which demonstrates that these electrophiles are indeed toxic. In the presence of superoxide, we have shown that LPO catalyzes the production of another electrophile, urate hydroperoxide. The suggested structure and formation of urate hydroperoxide via the addition of superoxide to the urate radical are shown in Fig. 1. We would expect urate hydroperoxides to make additional contributions to oxidative stress and propagate the toxicity of superoxide (62). However, in a physiological environment, antioxidants such as ascorbate may interfere by reducing urate radicals and limiting the formation of the electrophilic species of urate. The effects of ascorbate on the LPO/urate system will be the subject of future studies.

Stopped-flow kinetics showed that the rate constant for urate oxidation by compound I (1 × 10^-4 M s^-1) is the largest for any organic substrate of LPO studied to date (29). It is 5-fold greater than that for serotonin (E^0' (serotonin')/serotonin) = 0.65 V), the next best organic substrate, and similar to that for nitrite (2 × 10^-4 M s^-1) (63). The low reduction potential of urate (E^0' (urate')/urate) = 0.56 V) (20) should facilitate its oxidation by compound I. Additionally, its negative charge, like
Urate Oxidation by Lactoperoxidase

FIGURE 11. Suggested catalytic mechanism of LPO in an environment where similar concentrations of thiocyanate and urate are present. At low concentrations of hydrogen peroxide, urate will compete with thiocyanate for reaction with compound I (Cmpd I). Which substrate dominates will depend on their relative local concentrations. Urate will also ensure that LPO is not trapped at compound II (Cmpd II), thereby ensuring continual oxidant production by the enzyme. At high concentrations of hydrogen peroxide, LPO will be converted compound III (Cmpd III), whereas its conversion back to compound II relies on its slow release of oxygen (55). Under these conditions, the bactericidal activity of LPO will be inhibited.

that of nitrite ($E^\prime\prime_{\text{NO}_2^-} = 0.99 \text{ V}$), may also assist its binding in the active site and subsequent oxidation. Indeed, the rate constant for oxidation of urate by compound I of LPO is markedly greater than that for compound I of MPO ($4.6 \times 10^5 \text{ M}^{-1} \text{s}^{-1}$) (23), although the redox potential of the compound I/compound II couple is higher for MPO than LPO (1.35 versus 1.14 V) (51). The stereoelectronic characteristics of the substrate binding site in LPO are responsible for the favorable orientation of thiocyanate, when compared with MPO, and may therefore also favor binding and subsequent oxidation of urate (64).

The rate constant for reduction of compound II by urate ($8.5 \times 10^3 \text{ M}^{-1} \text{s}^{-1}$) was derived by fitting the linear portion of the plot of the observed rate constants versus urate concentration. Its magnitude is comparable with that for other organic substrates of LPO but substantially less than that for serotonin ($3.0 \times 10^5 \text{ M}^{-1} \text{s}^{-1}$) (29), suggesting that negative charge and reduction potential have less influence on oxidation of substrates by this redox intermediate. Rather binding to the active site may be the crucial factor in substrate oxidation, which is supported by fact that the plot of the observed rate constants versus urate concentration plateaus for this reaction at high urate concentrations. The rate constant for oxidation by compound II is also comparable with that for MPO ($1.7 \times 10^4 \text{ M}^{-1} \text{s}^{-1}$) (23). In this case, the compound II/ferric couples for MPO and LPO are similar (0.97 versus 1.04 V) (65). The similarity of the kinetic and thermodynamic parameters suggests that urate occupies a similar position in the compound II forms of these peroxidases. The apparent dissociation constant ($200 \mu\text{M}$) for urate binding to LPO compound II is comparable with the Michaelis-Menten constant ($100 \mu\text{M}$) we found during steady state turnover of urate, suggesting that the binding interaction of urate and compound II represents the rate-determining step in the reduction of compound II.

LPO has previously been described as capable of producing two forms of compound I and II (50, 66), where the electron hole is stored either as a radical cation on the porphyrin ring or as an amino acid-based radical, depending on the pH. However, we found that regardless of whether the compound II species was formed by slow decay of compound I or fast reduction by urate, it reacted at the same rate with urate to form ferric LPO. Consequently, we have no evidence for more than one species of compound II under our experimental conditions.

Steady state kinetic studies of LPO oxidation of thiocyanate provided constants that are comparable with those that have been determined previously for thiocyanate turnover by both myeloperoxidase and eosinophil peroxidase (56, 67). However, they reveal major discrepancies when compared with the values previously published for thiocyanate oxidation by LPO (68). These discrepancies are most likely due to differences in experimental conditions; the previous study was conducted at pH 5.5 and at hydrogen peroxide concentrations ranging from 0.5 to 1 mM. The experiments presented here were carried out at neutral pH and with comparably low hydrogen peroxide concentrations ($100 \mu\text{M}$). We believe that our experimental conditions represent more closely the physiological environment, and at the same time minimize undesired irreversible inhibition of the enzyme.

The steady state oxidation of urate by LPO was characterized by biphasic kinetics with an initial fast phase followed by a slower second phase. Activity assays showed that LPO was not irreversibly inhibited by urate or by its oxidation products. Spectroscopic studies suggest that the initial fast phase represents urate turnover during the classical peroxidase cycle, whereas the subsequent slower phase represents a second turnover cycle, where the enzyme rapidly converts to compound III and subsequently reverts to compound II at a slower rate (Fig. 11). An analogous mechanism has previously been demonstrated for oxidation of nitrite and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) by LPO (63). Using stopped-flow spectroscopy, we were able to show that compound III is formed during the steady state of urate oxidation, and its formation was linearly dependent on hydrogen peroxide concentration. This plot intersected the origin, which excludes the possibility that compound III is formed either reversibly or via a second route, e.g. by the addition of superoxide to the native enzyme or by reduction of the ferric enzyme and subsequent to the addition of dioxygen. Consequently, urate and hydrogen peroxide compete for reaction with compound II under multiple turnover conditions with the eventual conversion of the enzyme to compound III.

The Michaelis-Menten parameters of urate turnover during the initial steady state phase (Table 1) reflect the capability of urate to compete effectively with thiocyanate for oxidation. However, on the longer time scale, it was apparent that inhibition of hypothiocyanite production cannot be simply explained by urate and thiocyanate acting as competitive substrates for compound I. Instead, reaction of hydrogen peroxide with compound II and diversion of the enzyme away from the halogenation cycle must be invoked to clarify the mechanism of inhibition. Thus, it appears that the slower second cycle is integral in describing modulation of LPO activity. This reaction has...
important consequences because we found that under physiologically plausible conditions, urate inhibited LPO-dependent killing of *P. aeruginosa* by preventing the enzyme from producing hypothyocyanate.

Our work on human saliva supports the proposal that urate is a physiological substrate for LPO. In agreement with previous studies, we found that LPO was the dominant peroxidase in saliva supernatants, and there were also variable concentrations of MPO present (25, 58). LPO, but not MPO content, was correlated with allantoin in saliva. Ex vivo experiments demonstrated that peroxidase activity was required for oxidation of urate in saliva supernatants and was dependent on the urate concentration. Given the fact that urate was oxidized in saliva with low MPO, including that from an individual with MPO deficiency, it is apparent that LPO contributes to the production of allantoin in saliva. The degree of urate oxidation was reliant on urate concentration, which is expected because saliva contains high concentrations of thiocyanate (0.5–2 mm) (25). Hence, the higher the concentration of urate, the more likely it would compete with thiocyanate for oxidation by compound I of LPO. It is conceivable that other proteins in saliva contain pseudo-peroxidase activity. However, previous work established that LPO and MPO were by far the dominant peroxidases in saliva supernatants (25, 58). Consequently, any pseudo-peroxidase activity would not compete with much higher concentrations of LPO, especially because urate is an excellent substrate for this enzyme.

Exactly how urate affects LPO activity in vivo will depend on the relative concentrations of urate and thiocyanate as well as the steady state concentration of hydrogen peroxide. From this work, it is apparent that the major determinant of LPO activity in vivo will be the local flux of hydrogen peroxide. Under conditions where hydrogen peroxide produced by NADPH oxidases or xanthine oxidoreductase does not accumulate, LPO is expected to oxidize thiocyanate via the halogenation cycle and to oxidize urate via the peroxidase cycle. However, under conditions where oxidase activity exceeds peroxidase activity and hydrogen peroxide accumulates, then LPO will be largely inhibited as urate reduces it to compound II and hydrogen peroxide diverts it to compound III. Consequently, information on the in vivo steady state concentrations of hydrogen peroxide is required before we can fully appreciate the biological action of LPO. However, it is clear from this work that urate and thiocyanate should be considered as competing physiological substrates for LPO. They are present in airway lining fluids at largely varying concentration ranges (urate: 40–370 μM, thiocyanate: 50–400 μM) (19, 69), so they will compete for oxidation by compound I. It is likely that under most circumstances thiocyanate is the preferred substrate for compound II and urate will act simply by preventing accumulation of compound II and maintaining production of hypothyocyanate. Under some situations, however, it is possible that urate could be the major substrate for compound I. For example, in hyperuricemic individuals who have a diet low in thiocyanate, urate may be the major substrate. This situation is a potential problem in patients with cystic fibrosis who are prone to hyperuricemia (70) and also have defective transport of thiocyanate into the epithelial lining fluid of their lungs (71). Consequently, LPO, which is present in the airways, would be less effective at producing hypothyocyanate and combatting the frequent infections these patients suffer, but likely to generate potentially harmful electrophiles.

In conclusion, our work has shown that urate reacts rapidly with compound I of LPO and is therefore a likely physiological substrate for LPO under conditions of relatively high urate concentration when compared with thiocyanate. This reaction may thus affect host defense by influencing the bacterial activity of this enzyme. Further research should be focused on how hydrogen peroxide, thiocyanate, and urate interact in vivo to modulate the activity of LPO and whether the electrophilic species generated from urate oxidation are toxic to either invading bacteria or the host cells.

REFERENCES

1. Becker, B. F. (1993) Towards the physiological function of uric acid. *Free Radic. Biol. Med.* **14**, 615–631
2. Frei, B., Stocker, R., and Ames, B. N. (1988) Antioxidant defenses and lipid peroxidation in human blood plasma. *Proc. Natl. Acad. Sci. U.S.A.* **85**, 9748–9752
3. Wayner, D. M., Burton, G. W., Ingold, K. U., Barclay, L. R. C., and Locke, S. J. (1987) The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. *Biochim. Biophys. Acta* **924**, 408–419
4. Uotila, J., Metsa-Ketela, T., and Tuimala, R. (1992) Plasma peroxyl radical-trapping capacity in severe preeclampsia is strongly related to uric acid. *Clin. Exp. Hypertens.* **B11**, 71–80
5. Peden, D. B., Hohman, R., Brown, M. E., Mason, R. T., Berkebile, C., Fales, H. M., and Kaliner, M. A. (1990) Uric acid is a major antioxidant in human nasal airway secretions. *Proc. Natl. Acad. Sci. U.S.A.* **87**, 7638–7642
6. Shi, Y. (2010) Caught red-handed: uric acid is an agent of inflammation. *J. Clin. Invest.* **120**, 1809–1811
7. Alvarez-Lario, B., and Macarron-Vicente, J. (2010) Uric acid and evolution. *Rheumatology* **49**, 2010–2015
8. Merriman, T. R., and Dalbeth, N. (2011) The genetic basis of hyperuricaemia and gout. *Joint Bone Spine* **78**, 35–40
9. Cannon, P. J., Stason, W. B., Demartini, F. E., Sommers, S. C., and Laragh, J. H. (1966) Hyperuricemia in primary and renal hypertension. *N. Engl. J. Med.* **275**, 457–464
10. Ford, E. S., Li, C., Cook, S., and Choi, H. K. (2007) Serum concentrations of uric acid and the metabolic syndrome among us children and adolescents. *Circulation* **115**, 2526–2532
11. Goodarznejad, H., Anvari, M. S., Boroumand, M. A., Karimi, A., Abbasi, S. H., and Davoodi, G. (2010) Hyperuricemia and the presence and severity of coronary artery disease. *Lab. Med.* **41**, 40–45
12. Lehto, S., Niskanen, L., Rönnemaa, T., and Laakso, M. (1998) Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* **29**, 635–639
13. Feig, D. I., Kang, D.-H., and Johnson, R. J. (2008) Uric acid and cardiovascular risk. *N. Engl. J. Med.* **359**, 1811–1821
14. Krishnan, E. (2011) Uric acid in heart disease: A new c-reactive protein? *Curr. Opin. Rheumatol.* **23**, 174–177
15. Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., and Johnson, R. J. (2002) A role for uric acid in the progression of renal disease. *J. Am. Soc. Nephrol.* **13**, 2888–2897
16. Kutzing, M. K., and Firestein, B. L. (2008) Altered uric acid levels and disease states. *J. Pharmacol. Exp. Ther.* **324**, 1–7
17. Choi, H. K., Mount, D. B., and Reginato, A. M. (2005) Pathogenesis of gout. *Ann. Intern. Med.* **143**, 499–516
18. Johnson, R. J., and Rideout, B. A. (2004) Uric acid and diet: insights into the epidemic of cardiovascular disease. *N. Engl. J. Med.* **350**, 1071–1073
19. van der Vliet, A., O’Neill, C. A., Cross, C. E., Koostra, J. M., Volz, W. G., Halliwell, B., and Louie, S. (1999) Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids. *Am. J.*
Uruguay Oxidation by Lactoperoxidase

Physical. 276, L289–L296
20. Buettner, G. R. (1993) The pecking order of free radicals and antioxidants: Lipid peroxidation, α-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535–543
21. Canellakis, E. S., Tuttle, A. L., and Cohen, P. P. (1955) A comparative study of the end-products of uric acid oxidation by peroxidases. J. Biol. Chem. 213, 397–404
22. Lewstal, R. A. (1984) Effect of urate on the lactoperoxidase catalyzed oxidation of adrenaline. BioMetals 17, 631–634
23. Meotti, F. C., Jameson, G. N. L., Turner, R., Harwood, D. T., Stockwell, S., Rees, M. D., Thomas, S. R., and Ketke, A. J. (2011) Urate as a physiological substrate for myeloperoxidase. J. Biol. Chem. 286, 12901–12911
24. Ogino, M., Yamamoto, S., Hayaishi, O., and Tokuyama, T. (1979) Isolation and activity of myeloperoxidase. [25. Ihalin, R., Loimaranta, V., and Tenovuo, J. (1998) The pecking order of free radicals and antioxidants: An anaerobic stopped-flow study. Arch. Biochem. Biophys. 398, 12–22
26. Furtmüller, P. G., Jantschko, W., Regelsberger, G., Jakopitsch, C., Arnhold, J., and Obinger, C. (2002) Reaction of lactoperoxidase compound i with halides and thiocyanate: Biochemistry 41, 11895–11900
27. Nagy P., Alguindigue, S. S., and Ashby, M. T. (2006) Lactoperoxidase-catalyzed oxidation of thiocyanate by hydrogen peroxide: A reinvestigation of hypothiocyanite by nuclear magnetic resonance and optical spectroscopy. Biochemistry 45, 12610–12616
28. Wijkstöm-Frei, C., El-Chemaly, S., Ali-Rachedi, R., Gerson, C., Cobas, M. A., Forteza, R., Salathe, M., and Conner, G. E. (2003) Lipid peroxidation, and ascorbate. Biochemistry 42, 51–59
29. Pruitt, K. M., Mansson-Rahemtulla, B., Baldone, D. C., and Rahemtulla, F. (2005) in The Lactoperoxidase System, Chemistry and Biological Significance (Pruitt, K. M., Tenovuo, J. O., ed) pp. 15–29, Marcel Dekker, New York
30. Pruitt, K. M., Mansson-Rahemtulla, B., Baldone, D. C., and Rahemtulla, F. (1988) Steady-state kinetics of thiocyanate oxidation catalyzed by human airway host defense. J. Biol. Chem. 263, 906–913
31. Metodiewa, D., and Dunford, H. B. (1990) Evidence for one-electron oxidation of benzylpenicillin g by lactoperoxidase compounds i and ii. Biochem. Biophys. Res. Commun. 169, 1211–1216
32. Paul, K. G., and Ohlsson, P. I. (1985) in The Lactoperoxidase System, Chemistry and Biological Significance (Pruitt, K. M., Tenovuo, J. O., ed) pp. 15–29, Marcel Dekker, New York
33. McCord, J. M., and Fridovich, I. (1959) The microestimation of succinate and the extinction coefficient of cytochrome c. Biochim. Biophys. Acta 34, 255–256
34. Wolff, S. P. (1994) Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol. 233, 182–189
35. McCord, J. M., and Fridovich, I. (1968) The reduction of cytochrome c by hydrogen peroxide and dioxygen: An anaerobic stopped-flow study. Arch. Biochem. Biophys. 126, 1211–1216
36. Marquez, L. A., Dunford, H. B., and Van Wart, H. (1990) Kinetic studies on the reaction of compound ii of myeloperoxidase with ascorbic acid. Role of ascorbic acid in myeloperoxidase function. J. Biol. Chem. 265, 5666–5670
37. Queiroz, R. F., Vaz, S. M., and Augusto, O. (2011) Inhibition of the chlorinating activity of myeloperoxidase by tempol revisiting the kinetics and mechanisms. Biochem. J. 439, 423–431
38. Schmid, R., and Sapunov, V. N. (1982) Non-formal kinetics, pp. 32–34, Verlag Chemie, Weinheim, Germany
39. Jantschko, W., Furtmüller, P. G., Zederbauer, M., Jakopitsch, C., and Obinger, C. (2005) Standard reduction potentials of all couples of an activator for prostaglandin hydroperoxidase from bovine vesicular gland cystein and its identification as uric acid. Biochemistry. Biochim. Biophys. Res. Commun. 87, 184–191
40. Fridovich, I. (1985) in Handbook of Methods for Oxygen Radical Research (Greenwald, R. A., ed) pp. 51–53, CRC Press Inc., Boca Raton, Fl.
41. Massey, V. (1959) The microestimation of succinate and the extinction coefficient of cytochrome c. Biochim. Biophys. Acta 34, 255–256
42. Wolff, S. P. (1994) Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol. 233, 182–189
43. Nirmala, J., and Sastry, K. S. (1975) Photodecomposition of uric acid. Indian J. Biochem. Biophys. 12, 47–50
44. Markwardt, P. (1993) The pecking order of free radicals and antioxidants: Lipid peroxidation, α-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535–543
45. McCord, J. M., and Fridovich, I. (1968) The reduction of cytochrome c by hydrogen peroxide and dioxygen: An anaerobic stopped-flow study. Arch. Biochem. Biophys. 126, 1211–1216
46. Marquez, L. A., Dunford, H. B., and Van Wart, H. (1990) Kinetic studies on the reaction of compound ii of myeloperoxidase with ascorbic acid. Role of ascorbic acid in myeloperoxidase function. J. Biol. Chem. 265, 5666–5670
47. Queiroz, R. F., Vaz, S. M., and Augusto, O. (2011) Inhibition of the chlorinating activity of myeloperoxidase by tempol revisiting the kinetics and mechanisms. Biochem. J. 439, 423–431
48. Schmid, R., and Sapunov, V. N. (1982) Non-formal kinetics, pp. 32–34, Verlag Chemie, Weinheim, Germany
49. Jantschko, W., Furtmüller, P. G., Zederbauer, M., Jakopitsch, C., and Obinger, C. (2005) Reaction of ferrous lactoperoxidase with hydrogen peroxide and dioxygen: An anaerobic stopped-flow study. Arch. Biochem. Biophys. 434, 51–59
50. van Dalen, C. J., and Kettle, A. J. (2001) Substrates and products of eosinophil peroxidase. Biochem. J. 358, 233–239
51. Tahboub, Y. R., Galijasevic, S., Diamond, M. P., and Abu-Soud, H. M. (2005) Thiocyanate modulates the catalytic activity of mammalian peroxidases. J. Biol. Chem. 280, 26129–26136
52. Thomas, E. L., Jefferson, M. P., Joyner, R. E., Cook, G. S., and King, C. C. (1994) Leukocyte myeloperoxidase and salivary lactoperoxidase: Identification and quantitation in human mixed saliva. J. Dent. Res. 73, 544–555
53. Vilja, P., Lumikari, M., Tenovuo, J., Sievers, G., and Tuohimaa, P. (1991) Sensitive immunometric assays for secretory peroxidase and myeloperoxidase in human saliva. J. Immunol. Methods 141, 277–284
54. Volk, K. J., Yost, R. A., and Brajer-Toth, A. (1990) On-line mass spectrometric investigation of the peroxidase-catalysed oxidation of uric acid. J. Pharm. Biomed. Anal. 8, 205–215
55. Stevenson, W. S., Hyland, C. D., Zhang, I.-G., Morgan, P. O., Willson, T. A., Gill, A., Hilton, A. A., Viney, E. M., Bahlo, M., Masters, S. L., Henebry, S., Richardson, S. J., Nicola, N. A., Metcalfe, D., Hilton, D. J., Roberts, A. W., and Alexander, W. S. (2010) Deficiency of 5-hydroxyisouresyl hydroxylase causes hepateomaligemia and hepatocellular carcinoma in mice. Proc. Natl. Acad. Sci. U.S.A. 107, 16625–16630
56. Winterbourn, C. C., and Kettle, A. J. (2003) Radical-radical reactions of superoxide: a potential route to toxicity. Biochem. Biophys. Res. Commun. 305, 729–736
57. Brück, T. B., Fielding, R. J., Symons, M. C. R., and Harvey, P. J. (2001) Mechanism of nitrate-stimulated catalysis by lactoperoxidase lactoperoxidase catalysis and nitrite stimulation. Eur. J. Biochem. 268, 3214–3222
64. Sharma, S., Singh, A. K., Kaushik, S., Sinha, M., Singh, R. P., Sharma, P., Sirohi, H., Kaur, P., and Singh, T. P. (2013) Lactoperoxidase: structural insights into the function, ligand binding and inhibition. *Int. J. Biochem. Mol. Biol.* 4, 108–128

65. Furtmüller, P. G., Zederbauer, M., Jantschko, W., Helm, J., Bogner, M., Jakopitsch, C., and Obinger, C. (2006) Active site structure and catalytic mechanisms of human peroxidases. *Arch. Biochem. Biophys.* 445, 199–213

66. Monzani, E., Gatti, A. L., Profumo, A., Casella, L., and Gullotti, M. (1997) Oxidation of phenolic compounds by lactoperoxidase. Evidence for the presence of a low-potential compound ii during catalytic turnover. *Biochemistry* 36, 1918–1926

67. van Dalen, C. J., Whitehouse, M. W., Winterbourn, C. C., and Kettle, A. J. (1997) Thiocyanate and chloride as competing substrates for myeloperoxidase. *Biochem. J.* 327, 487–492

68. Ghibaudi, E., Laurenti, E., Pacchiardo, C., Suriano, G., Moguilevsky, N., and Pia Ferrari, R. (2003) Organic and inorganic substrates as probes for comparing native bovine lactoperoxidase and recombinant human myeloperoxidase. *J. Inorg. Biochem.* 94, 146–154

69. Lorentzen, D., Durairaj, L., Pezzulo, A. A., Nakano, Y., Launspach, J., Stoltz, D. A., Zamba, G., McCray, P. B., Jr., Zabner, J., Welsh, M. J., Nauseef, W. M., and Bánfi, B. (2011) Concentration of the antibacterial pre-cursor thiocyanate in cystic fibrosis airway secretions. *Free Radic. Biol. Med.* 50, 1144–1150

70. Horsley, A., Helm, J., Brennan, A., Bright-Thomas, R., Webb, K., and Jones, A. (2011) Gout and hyperuricaemia in adults with cystic fibrosis. *J. R. Soc. Med.* 104, S36–S39

71. Conner, G. E., Wijkstrom-Frei, C., Randell, S. H., Fernandez, V. E., and Salathe, M. (2007) The lactoperoxidase system links anion transport to host defense in cystic fibrosis. *FEBS Lett.* 581, 271–278